Patients with the autoimmune disease systemic lupus erythematosus (SLE) develop pathogenic antibodies against their own self-antigens. U1-70(131-150):I-Ek (without phosphorylation) correlates with disease intensity and antiCU1-70 autoantibody creation. These T cells express RORt and produce IL-17A also. Furthermore, the U1-70Cparticular Compact disc4+ T cells that generate IL-17A are discovered within a subset of sufferers Dovitinib with SLE and so are significantly elevated in sufferers with blended connective tissues disease. These scholarly research offer equipment for learning antigen-specific POLDS Compact disc4+ T cells in lupus, and show an Dovitinib antigen-specific way to obtain IL-17A in autoimmune disease. Systemic lupus erythematosus (SLE) can be an autoimmune disease where sufferers develop high-titer, specific highly, isotype-switched autoantibodies against DNA- and RNA- filled with autoantigens (1). U1-70, U1-A, and U1-C, with U1-RNA as well as the seven Smith proteins jointly, ...
OBJECTIVES: To perform systematic assessment of ovarian reserve markers using a combination of tests in juvenile systemic lupus erythematosus (JSLE) patients without amenorrhoea. METHODS: Twenty-seven consecutive JSLE female patients and 13 healthy c
Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies ≥1:80 and/or anti-double-stranded DNA antibodies ≥30 IU/ml) at baseline was retrospectively evaluated using the SRI. ...
Clinical trial for SYSTEMIC LUPUS ERYTHEMATOSUS , Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
TY - JOUR. T1 - Possible triggering effect of cytomegalovirus infection on systemic lupus erythematosus. AU - Nawata, M.. AU - Seta, N.. AU - Yamada, M.. AU - Sekigawa, I.. AU - Iida, N.. AU - Hashimoto, H.. PY - 2001. Y1 - 2001. N2 - We report on a patient with systemic lupus erythematosus (SLE) who showed elevated titers of IgM antibodies to cytomegalovirus (CMV), suggesting CMV infection at the onset of SLE. Serum CMV antigens were also detected in the patient. These findings raise the possibility that CMV infection may be related to the onset of SLE in certain patients.. AB - We report on a patient with systemic lupus erythematosus (SLE) who showed elevated titers of IgM antibodies to cytomegalovirus (CMV), suggesting CMV infection at the onset of SLE. Serum CMV antigens were also detected in the patient. These findings raise the possibility that CMV infection may be related to the onset of SLE in certain patients.. KW - Cytomegalovirus. KW - Proteinuria. KW - Systemic lupus ...
Immunoglobulin M (IgM) autoreactivity to malondialdehyde (MDA) protein modifications is part of the natural antibody repertoire in health and may have beneficial functions. In contrast, IgG anti-MDA are increased in chronic inflammation and autoimmunity and may instead have pathogenic properties. Herein, we investigated serum IgG anti-MDA levels by enzyme-linked immunosorbent assay (ELISA) in 398 systemic lupus erythematosus (SLE) patients in the Swedish Karolinska SLE cohort and compared these to findings in 225 US SLE patients from New York University and Johns Hopkins University. In two independent cohorts, IgG anti-MDA levels correlated positively with disease activity by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; p | 0.0001, Spearman R = 0.3). Meta-analysis found an odds ratio of 2.7 (confidence interval (CI) 1.9-3.9; p | 0.0001) for high anti-MDA IgG levels with active disease (SLEDAI ≥ 6). Furthermore, IgG anti-MDA correlated directly with erythrocyte sedimentation rate
An SRI response is defined as a reduction from baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) score of at least 4 points, no worsening in Physicians Global Assessment (PhGA) (with worsening defined as an increase in PhGA of more than 0.30 point from baseline), no British Isles Lupus Assessment Group A (BILAG A) organ domain score, and no more than 1 new BILAG B organ domain score from baseline ...
Systemic lupus erythematosus: Find the most comprehensive real-world symptom and treatment data on systemic lupus erythematosus at PatientsLikeMe. 37842 patients with systemic lupus erythematosus experience muscle pain, joint swelling, skin sensitivity to sun (photosensitivity), joint pain, and chest pain and use Hydroxychloroquine, Prednisone, Methotrexate, Belimumab, and Azathioprine to treat their systemic lupus erythematosus and its symptoms.
Results The serum levels of sCXCL16 in jSLE patients were higher than controls (p,0.001), they were also siginificantly higher in patients with alopecia or malar rash than other jSLE .Positive correlation was identified between serum levels of sCXCL16 and SLEDAI score. There was a significant positive correlation between sCXCL16 levels and severity of lupus nephritis as assessed by renal biopsy. Serum levels of sCXCL16 were positively significantly correlated with the 24 hour urine protein,ANA, SBP, DBP AND ESR 1st hour. Serum sCXCL16 level was significanly negatively correlated with C3 serum level. ...
Autoantibodies against complement C1q (anti-C1q Abs) were shown to strongly correlate with the occurrence of severe nephritis in patients with systemic lupus erythematosus (SLE), suggesting a potential pathogenic role by interfering with the complement cascade. To analyze the humoral immune response against C1q at the molecular level, we screened a bone marrow-derived IgGkappa/IgGlambda Fab phage display library from a SLE patient with high anti-C1q Ab titer against purified human C1q. Six Fabs that exhibited strong binding to C1q in ELISA were isolated. The anti-C1q Fabs recognized neoepitopes that were only exposed on bound C1q and not present on soluble C1q mapping to different regions of the collagen-like region of C1q. Analysis of the genes encoding the variable H and L chains of the IgG-derived anti-C1q Fab revealed that all the variable H and L chain regions were highly mutated, with nucleotide and amino acid homologies to the closest germline in the range of 71-97% (average 85 +/- 4) and ...
TY - JOUR. T1 - Cardiac pathology of systemic lupus erythematosus. AU - Jain, D.. AU - Halushka, Marc K. PY - 2009/7. Y1 - 2009/7. N2 - Systemic lupus erythematosus is a common chronic autoimmune disorder causing injury to many organ systems. Cardiac complications of lupus affect most parts of the heart. These include pericarditis, myocarditis, endocarditis and coronary artery disease. While many histopathological findings in lupus-related cardiac diseases are non-specific, there are a few important findings which pathologists should be aware of. This review provides pathological descriptions of these entities.. AB - Systemic lupus erythematosus is a common chronic autoimmune disorder causing injury to many organ systems. Cardiac complications of lupus affect most parts of the heart. These include pericarditis, myocarditis, endocarditis and coronary artery disease. While many histopathological findings in lupus-related cardiac diseases are non-specific, there are a few important findings which ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Results The mean age of the JSLE children was 13.25±2.09 years and 23.17±4.26 years for JO-SLE cases. JO-SLE cases were older at disease onset with a higher female-to-male ratio. There were no noticeable gender differences. There was a significantly higher frequency of serositis, nephritis and hematological involvement in the JO-SLE (57.7%, 76.9% and 73.1%) compared to the JSLE cases (15.4%; 30.8% and 30.8%) (p,0.001 for all). The erythrocyte sedimentation rate, creatinine and proteinuria were significantly increased in JO-SLE while alkaline phosphatase was higher in JSLE cases. In JO-SLE cases, SLEDAI significantly increased (5.96±6.18 vs 3.12±1.97; p=0.003) and the SLICC tended to increase compared to the JSLE children. More JO-SLE cases received hydroxychloroquine and azathioprine. ...
Is melasma a symptom of systemic lupus erythematosus sle - Is there a cure for systemic lupus erythematosus (sle)? SLE treatment. Systemic lupus erythematosus (sle) is a long-term autoimmune disorder that may affect the skin, joints, kidneys, brain, and other organs. There is no cure for sle. The goal of treatment is to control symptoms.
Systemic lupus erythematosus (SLE) is a rheumatic disease characterized by autoantibodies directed against self-antigens, immune complex formation, and immune dysregulation, resulting in damage to essentially any organ. The disease can affect, for example, the kidneys, skin, blood cells, and nervous system.
Table of Contents. Table of Contents 2. List of Tables 7. List of Figures 9. Introduction 10. Global Markets Direct Report Coverage 10. Systemic Lupus Erythematosus Overview 11. Therapeutics Development 12. Pipeline Products for Systemic Lupus Erythematosus-Overview 12. Pipeline Products for Systemic Lupus Erythematosus-Comparative Analysis 13. Systemic Lupus Erythematosus-Therapeutics under Development by Companies 14. Systemic Lupus Erythematosus-Therapeutics under Investigation by Universities/Institutes 19. Systemic Lupus Erythematosus-Pipeline Products Glance 20. Late Stage Products 20. Clinical Stage Products 21. Early Stage Products 22. Unknown Stage Products 23. Systemic Lupus Erythematosus-Products under Development by Companies 24. Systemic Lupus Erythematosus-Products under Investigation by Universities/Institutes 29. Systemic Lupus Erythematosus-Companies Involved in Therapeutics Development 30. 4SC AG 30. AbbVie Inc. 31. Ablynx NV 32. Actelion Ltd 33. AiCuris GmbH & Co. KG 34. Amgen ...
TY - JOUR. T1 - Echocardiographic observation of acute myocarditis with systemic lupus erythematosus. AU - Ueda, Takashi. AU - Mizushige, Katsufumi. AU - Aoyama, Tohru. AU - Tokuda, Michiaki. AU - Kiyomoto, Hideyasu. AU - Matsuo, Hirohide. PY - 2000/2/1. Y1 - 2000/2/1. N2 - Although myocarditis from a series of autopsies of patients with systemic lupus erythematosus was frequently observed, the incidence of clinically apparent myocardial dysfunction was low. A 30-year-old woman with systemic lupus erythematosus was examined by echocardiography. An acoustic densitometry was followed at the left ventricular posterior wall throughout the clinical course. A decrease in the magnitude of cyclic variation of integrated backscatter (IB) was observed before treatment. Following the combined treatment, steroid and cyclophosphamide, a repeated ultrasonic tissue characterization showed an increase in the magnitude of cyclic variation of IB. It is thought that ultrasonic tissue characterization may be a ...
Systemic lupus erythematosus Bluish complexion, Bluish skin, Blue-tinge to the skin, Cough with cloudy, fishy-smelling mucus, Cough with cloudy, fishy-smelling sputum, , Chronic constipation (elderly people), , systemic lupus erythematosus
Get information, facts, and pictures about Systemic Lupus Erythematosus at Encyclopedia.com. Make research projects and school reports about Systemic Lupus Erythematosus easy with credible articles from our FREE, online encyclopedia and dictionary.
The purpose of the present study was to compare dynamic muscle strength, functional performance, fatigue, and quality of life in premenopausal systemic lupus erythematosus (SLE) patients with low disease activity versus matched-healthy controls and to determine the association of dynamic muscle strength with fatigue, functional performance, and quality of life in SLE patients. We evaluated premenopausal (18-45 years) SLE patients with low disease activity (Systemic lupus erythematosus disease activity index [SLEDAI]: mean 1.5 ± 1.2). The control (n = 25) and patient (n = 25) groups were matched by age, physical characteristics, and the level of physical activities in daily life (International Physical Activity Questionnaire IPAQ). Both groups had not participated in regular exercise programs for at least six months prior to the study. Dynamic muscle strength was assessed by one-repetition maximum (1-RM) tests. Functional performance was assessed by the Timed Up and Go (TUG), in 30-s test a chair stand
To explore the inadequacies of health service and its impact on clinical outcomes of patients with systemic lupus erythematosus (SLE) in China. A total of 210 SLE patients were randomly recruited between January 2017 and January 2018. Each patient received self-report questionnaires to assess medication adherence [Compliance Questionnaire for Rheumatology (CQR)], beliefs about medicines [Beliefs about Medicines Questionnaire (BMQ)] and satisfaction about medicine information [the Satisfaction with Information about Medicines Scale (SIMS)]. Associations between SLE disease activity index (SLEDAI-2 K) and observed factors were analyzed by multiple logistic regression. Based on CQR, only 28.10% patients were adherent. The score of BMQ was 2.85 ± 5.42, and merely 32.38% patients were satisfied with the information about their prescribed medicines. Disease activity was associated with SIMS, EuroQol five-dimensions [EQ5D], Systemic Lupus International Collaborating Clinics (SLICC), depression, use of NSAID
Group A only: patients on immunosuppressive treatments had them withdrawn at baseline. All patients were allowed up to 160 mg depomedrol at baseline which could be repeated within two weeks up to a total of 4 shots maximum or until satisfactory improvement. Time to flare was calculated from baseline. moderate disease at baseline was defined as up to 3 BILAG B (moderate disease) organ scores, no BILAG A (severe disease) score and a SLEDAI ,/= 10. Severe disease required ,3 BILAG B, OR at least one BILAG A OR SLEDAI , 10 or meeting criteria for a severe flare on the SELENA SLEDAI flare index. At baseline 25 patients with moderate disease. 16 patients had severe disease. Note: severe rash with A on BILAG is only SLEDAI=2, explaining some discrepancies in measures ...
Keywords: Panretinal photocoagulation Retinal vascular occlusion Systemic lupus erythematosus Intro Systemic lupus erythematosus can be a multisystem disease of unfamiliar etiology seen as a several autoimmune phenomena with lesions in multiple body organ systems. Ocular manifestations of systemic BML-275 lupus erythematosus (SLE) consist of mucocutaneous involvement from the eyelids supplementary Sjogrens symptoms optic neuropathy. The retinopathy includes cotton wool spots with or without retinal hemorrhages generally.1-3 Vaso-occlusive disease particularly in the current presence of antiphospholipid antibodies usually trigger devastating and long term damage to visible function regardless of strenuous treatment and requires treatment with anticoagulation and proliferative retinopathy is treated with laser beam therapy.2 3 Case record A 35-year-old female was admitted due to sudden loss of visual acuity in the still left attention. She have been diagnosed as experiencing systemic lupus ...
Introduction: Patients with systemic lupus erythematosus (SLE) are at increased risk of metabolic syndrome (MetS) and its complications. In absence of..
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic, autoimmune disease. Genome-wide association studies (GWAS) have identified multiple risk SNPs in HLA and non-HLA gene regions. There is evidence that genetics are also important in lupus nephritis (LN) risk. LN is one of the most common and severe manifestations of SLE. The purpose of this study was to determine the association of known SLE risk SNPs with LN in both childhood-onset (cSLE) and adult-onset SLE (aSLE) populations. Methods: The study population included two tertiary care SLE cohorts; one with cSLE and the other with aSLE. Participants met American College of Rheumatology (ACR) and/or Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE, with prospectively collected clinical and laboratory data. Participants were genotyped on the Illumina MEGA or Omni1 arrays. Principal components were calculated in reference to the 1000 genomes project, and ancestry was genetically ...
Objective(s): Apoptosis is a tightly regulated process and plays a crucial role in autoimmune diseases. Because abnormalities in apoptosis are considered to be involved in the pathogenesis of systemic lupus erythematosus (SLE), in present study we studied the apoptosis in T lymphocytes from Iranian SLE patientsat protein and gene expression levels for some molecules which are involved in apoptosis pathways. Materials and Methods: Thirty five SLE patients (23 female, 12 male), and 20 age matched controls (10 female, 10 male) participated in this study. T lymphocytes were isolated from peripheral blood mononuclear cells (PBMCs) using MACS method. Apoptosis rate was studied at protein level by flow cytometer using Annexin V, and at gene expression level using semi-quantitative RT-PCR method for detection of Fas, FasL, Bcl-2, caspase 8, and caspase 9 genes. Results: The percentage of apoptotic cells in SLE patients was not different in comparison with controls (20.2% ± 1.4 vs 21.1% ± 1.0), but the
Data abstracted retrospectively from the charts at 11,359 clinic visits for 310 patients with SLE to the Montreal General Hospital were used to investigate the associations of recent corticosteroid dose and recent Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with 8 CHD risk factors (total serum cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein cholesterol, apolipoprotein B [Apo B], triglycerides, systolic blood pressure [BP], body mass index, and blood glucose) and the aggregate estimate of 2-year CHD risk. Separate multivariable linear regression models estimated the mutually-adjusted effects of average daily corticosteroid dose and average SLEDAI score within the past year on the current level of each risk factor while adjusting for age, sex, cumulative damage score, disease duration, and, where appropriate, use of relevant medications ...
Introduction Systemic Lupus Erythematosus (SLE) shows a spectrum of clinical manifestations that complicate its diagnosis, treatment and research. This variability is likely related with environmental exposures and genetic factors among which known SLE susceptibility loci are prime candidates. The first published analyses seem to indicate that this is the case for some of them, but results are still inconclusive and we aimed to further explore this question. Methods European SLE patients, 1444, recruited at 17 centres from 10 countries were analyzed. Genotypes for 26 SLE associated SNPs were compared between patients with and without each of 11 clinical features: ten of the American College of Rheumatology (ACR) classification criteria (except ANAs) and age of disease onset. These analyses were adjusted for centre of recruitment, top ancestry informative markers, gender and time of follow-up. Overlap of samples with previous studies was excluded for assessing replication. Results There were three
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by production of autoantibodies and immune complex deposition in various organs. Aberrations in the T lymphocyte compartment and dysregulated cytokine production are key features of SLE pathogenesis and disease progression. Recently, the role of the interleukin (IL)-17/IL-23 axis in the pathogenesis of SLE has been reported. IL-23 and IL-23R are essential for expansion of pathogenic IL-17-producing T lymphocytes and have been shown to be important in the pathogenesis of lupus in animal models. In this study, the expression of IL-23R and IL-17 in CD4+ and CD8+ T lymphocytes in peripheral blood mononuclear cells (PBMCs) of SLE patients and control subjects were examined by flow cytometry. Twenty-nine SLE patients and 10 control subjects were recruited in this study. Patients were divided into active and inactive groups based on the SLE disease activity index (SLEDAI). As another disease control population, five psoriatic patients
INTRODUCTION: Pulmonary arterial hypertension is a complication of systemic lupus erythematosus. Mortality in pregnant patients with pulmonary arterial hypertension related to connective tissue disease is as high as 56%. The authors report the first case of a successful maternal-fetal outcome in a pregnant patient with systemic lupus erythematosus-associated pulmonary arterial hypertension treated with sildenafil and inhaled iloprost during pregnancy and until several weeks after caesarean section. CASE PRESENTATION: The case presented is of a 29-year-old woman with systemic lupus erythematosus and associated severe pulmonary arterial hypertension. Vasodilator therapy with bosentan and sildenafil, immunosuppressive therapy with prednisone, hydroxychloroquine and azathioprine and oral anticoagulation (phenprocoumon) had normalized her right ventricular over right atrial pressure when she was diagnosed in her 5th week of pregnancy. The teratogenic drugs bosentan and phenprocoumon were stopped, the ...
Objectives The aim of this study is to identify prognostic factors of persistent disease activity and long quiescence in systemic lupus erythematosus (SLE). Methods Patients enrolled in the Hopkins Lupus Cohort from 1987 to 2012, who attended at least three visits per year during 3 consecutive years following baseline and had available information on disease activity were included. Patterns of SLE disease activity over the 3-year period were defined as: persistent long quiescent (pLQ), persistent relapsing-remitting (pRR), persistent chronic active (pCA) and mixed based on Modified SLE Disease Activity Index (M-SLEDAI). Possible predictors of pCA (vs pLQ, pRR and mixed) and pLQ (vs pCA, pRR and mixed) were identified by univariate and multivariate logistic regression analyses. Results 916 patients were included. In the multivariate analysis, use of hydroxychloroquine (OR: 0.45, 95% CI 0.22 to 0.92, p=0.03), African American ethnicity (OR: 2.36, 95% CI 1.15 to 4.85, p=0.02) and baseline SLEDAI ...
TY - JOUR. T1 - Single-nucleotide polymorphisms in VKORC1 are risk factors for systemic lupus erythematosus in Asians. AU - Kaiser, Rachel. AU - Taylor, Kimberly E.. AU - Deng, Yun. AU - Zhao, Jian. AU - Li, Yonghong. AU - Nititham, Joanne. AU - Chang, Monica. AU - Catanese, Joseph. AU - Begovich, Ann B.. AU - Brown, Elizabeth E.. AU - Edberg, Jeffrey C.. AU - McGwin, Gerald. AU - Alarcón, Graciela S.. AU - Ramsey-Goldman, Rosalind. AU - Reveille, John D.. AU - Vila, Luis M.. AU - Petri, Michelle. AU - Kimberly, Robert P.. AU - Feng, Xuebing. AU - Sun, Lingyun. AU - Shen, Nan. AU - Li, Wei. AU - Lu, Jian Xin. AU - Wakeland, Edward K.. AU - Li, Quan Zhen. AU - Yang, Wanling. AU - Lau, Yu Lung. AU - Liu, Fei Lan. AU - Chang, Deh Ming. AU - Yu, Chack Yung. AU - Song, Yeong W.. AU - Tsao, Betty P.. AU - Criswell, Lindsey A.. PY - 2013/1. Y1 - 2013/1. N2 - Objective The increased risk of thrombosis in systemic lupus erythematosus (SLE) may be partially explained by interrelated genetic pathways for ...
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder characterized by broad clinical manifestations including cardiovascular and renal complications with periodic disease flares and significant morbidity and mortality. One of the main contributing factors to the pathology of SLE is the accumulation and impaired clearance of immune complexes of which the principle components are host auto-antigens and antibodies. The contribution of host lipids to the formation of these autoimmune complexes remains poorly defined. The aim of the present study was to identify and analyze candidate lipid autoantigens and their corresponding anti-lipid antibody responses in a well-defined SLE patient cohort using a combination of immunological and biophysical techniques. Disease monitoring in the SLE cohort was undertaken with serial British Isles Lupus Assessment Group (BILAG) scoring. Correlations between specific lipid/anti-lipid responses were investigated as disease activity developed from active flares
TY - JOUR. T1 - Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. AU - Alarcón, Graciela S.. AU - Roseman, J. M.. AU - McGwin, G.. AU - Uribe, A.. AU - Bastian, H. M.. AU - Fessler, B. J.. AU - Baethge, B. A.. AU - Friedman, A. W.. AU - Reveille, J. D.. AU - Toloza, S.. AU - Agee, B. S.. AU - Sanchez, M. L.. AU - Sowell, E.. AU - Johnson, B.. AU - Ho, K.. AU - Ahn, C.. AU - Sandoval, R.. AU - Charles, J.. AU - Wang, L. L.. AU - Hunnicutt, S.. AU - Vilá, L. M.. AU - Borges, W.. AU - Pinilla, C.. PY - 2004/2. Y1 - 2004/2. N2 - Objective. To examine the predictors of damage in a multiethnic cohort of systemic lupus erythematosus (SLE) patients with a specific focus on damage at baseline. Patients and methods. SLE patients from a multiethnic US (Hispanic, African-American and Caucasian) cohort (LUMINA: Lupus in Minority populations, Nature versus nurture) were included if they had ≥6 months of follow-up in the cohort. Damage was measured with the ...
Nervous system involvement in systemic lupus erythematosus.: In a retrospective analysis of 80 patients with systemic lupus erythematosus (SLE) seen over a 10-y
Cranial Computed Tomography in the Diagnosis of Systemic Lupus Erythematosus F. Gonzalez-Scarano, M D , R o b e r t P. Lisak, M D , Larissa T. Bilaniuk, M D , Robert A. Zirnrnerrnan, M D , Paul C. Atkins, M D , a n d B u r t o n Zweirnan, MD ~ ~~ T h e cranial c o m p u t e d tomograms of 29 patients w i t h systemic lupus erythematosus (SLE) were reviewed. T w e n t y two patients had a clinical course consistent w i t h central nervous system involvement. Of these, 20 had abnormal C T studies d u r i n g the course of t h e i r C N S symptoms. The most common finding was sulcal enlargement, either w i t h or w i t h o u t ventricular enlargement, a n d i t was p r o m i n e n t i n patients w i t h either psychosis or dementia. Infarcts and intracranial hemorrhages were seen as well. Seven CT studies w e r e obtained in SLE patients without a clear diagnosis of C N S involvement. O n l y o n e of these was abnormal. Gonzalez-Scarano F, Lisak RP, Bilaniuk LT, et al: Cranial computed tomography ...
TY - JOUR. T1 - Identification of a significant association of a single nucleotide polymorphism in TNXB with systemic lupus erythematosus in a Japanese population. AU - Kamatani, Yoichiro. AU - Matsuda, Koichi. AU - Ohishi, Tetsuya. AU - Ohtsubo, Shigeru. AU - Yamazaki, Keiko. AU - Iida, Aritoshi. AU - Hosono, Naoya. AU - Kubo, Michiaki. AU - Yumura, Wako. AU - Nitta, Kosaku. AU - Katagiri, Toyomasa. AU - Kawaguchi, Yasushi. AU - Kamatani, Naoyuki. AU - Nakamura, Yusuke. PY - 2008/1/1. Y1 - 2008/1/1. N2 - Systemic lupus erythematosus (SLE) is one of the common autoimmune diseases, with complex genetic components. Here, we report on a case-control association study of 178 SLE patients and 899 control subjects, using genome-wide gene-based single nucleotide polymorphism (SNP) markers. An SNP, rs3130342, in a 5 flanking region of the TNXB gene revealed a significant association with SLE [P = 0.000000930, odds ratio (OR) 3.11, with 95% confidence interval (95%CI) of 1.89-5.28] in a Japanese ...
Using RNA hybridization techniques, we examined the expression of proto-oncogenes associated with lymphocyte activation in vitro in patients with systemic lupus erythematosus and other autoimmune diseases. T and B lymphocytes from these patients were found to have significantly increased expression of c-myc, c-myb, and c-raf RNA when compared with those of normal individuals. Among the mononuclear cell subpopulations, B lymphocytes expressed higher levels of RNA for these proto-oncogenes compared with the T lymphocytes. Since prompt expression of these and other proto-oncogenes occurs in fibroblasts and lymphocytes following mitogenic stimulation, we propose that the present findings reflect the pathologically activated state of various lymphocytic subpopulations which is observed in systemic lupus erythematosus and in other autoimmune diseases. Endogenous and exogenous factors which lead to the expression of autoimmunity might share the induction of proto-oncogene expression as a common ...
TY - JOUR. T1 - Peripheral sensorimotor and autonomic neuropathy associated with systemic lupus erythematosus. T2 - Clinical, pathological and immunological features. AU - Mccombe, P. A.. AU - Mcleod, J. G.. AU - Pollard, J. D.. AU - Guo, Y. P.. AU - Ingall, T. J.. PY - 1987/4. Y1 - 1987/4. N2 - The clinical features and pathological findings in the sural nerves are described of 7 patients with peripheral neuropathy; in 4 cases the criteria for diagnosis of systemic lupus erythematosus (SLE) were satisfied and in 3 other cases there was serological evidence of an undifferentiated connective tissue disease, most probably SLE. The peripheral neuropathy was of a chronic sensorimotor type with predominantly sensory features and gradual onset. In 2 cases the presentation was asymmetric. One patient had autonomic dysfunction. The pathological findings in the biopsied sural nerves were those of axonal degeneration and vasculitis. In 6 nerves there was increased expression of Class II (Ia) antigen ...
Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients
Systemic lupus erythematosus presenting as pneumococcal septicaemia and septic arthritis. Possible involvement of interferon alfa in the pathogenesis of fever in systemic lupus erythematosus
Clinical trial for SYSTEMIC LUPUS ERYTHEMATOSUS , An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus
... ? Your Health Online A to Z directory of dealing with Systemic Lupus Erythematosus & Self Care Strategies for natural nutritional health food remedies
Whole hemolytic complement and three components (C1q, C4, and C3) were measured in pleural fluids obtained from 50 patients-23 with malignant disease, 6 with lupus erythematosus, 6 with rheumatoid arthritis, 3 with congestive heart failure, 3 with pulmonary embolism, and 9 in whom the cause of the pleural effusion was not ascertained. The mean values for whole complement and the three components were lowest in lupus erythematosus and rheumatoid arthritis patients. Compared with the malignant disease group, these differences were statistically significant (P , 0.01) for whole complement, C4, and C3. Anticomplementary activity was found in pleural fluids from some patients with lupus erythematosus or rheumatoid arthritis. This suggests that the pleural fluid complement depletion may be secondary to immunologic inactivation and that immune mechanisms may contribute to the development of Pleuritis in lupus erythematosus and rheumatoid arthritis. ...
Interleukin-34 (IL-34) was initially identified as an alternative ligand for the colony-stimulating factor-1 receptor (CSF-1R) to mediate the biology of mononuclear phagocytic cells. Recently, IL-34 was found to be associated with chronic inflammation, such as in rheumatoid arthritis (RA). Both RA and systemic lupus erythematosus (SLE) are multifactorial autoimmune diseases and are characterized by excessive immune and inflammatory responses. Thus, we investigated whether IL-34 is involved in the pathogenesis of SLE. In all, 78 SLE patients and 53 healthy controls were enrolled in the research. Enzyme-linked immunosorbent assay (ELISA) was employed to measure the concentrations of serological IL-34. Then serum IL-34 levels between the SLE group and healthy controls were analyzed by the Mann-Whitney U test. Meanwhile, the correlations between the serum IL-34 levels and disease activity indexes and other established serum markers were assessed. Furthermore, the serum IL-34 levels of 20 active SLE patients
OBJECTIVE: To determine the frequency of prolonged remission in systemic lupus erythematosus (SLE) using strict criteria for remission and to define disease characteristics and prognosis of patients achieving this state. To also determine the frequency of remission utilizing less restrictive definitions, such as allowing shorter period of disease quiescence, persistence of serological activity, or treatment in the absence of clinical disease. METHODS: Patients registered in the Lupus Clinic database between 1970 and 1997 with visits no more than 18 months apart were identified. Prolonged remission was defined as a 5-year consecutive period of no disease activity (SLE disease activity index, SLEDAI = 0) and without treatment (corticosteroids, antimalarials, or immunosuppressants). Prolonged serologically active, clinically quiescent (SACQ) was defined as active serology (elevated anti-dsDNA by Farr assay or hypocomplementemia) but no clinical activity on SLEDAI and no treatment. RESULTS: Seven ...
Patients with the autoimmune disease systemic lupus erythematosus (SLE) develop pathogenic antibodies against their own self-antigens. U1-70(131-150):I-Ek (without phosphorylation) correlates with disease intensity and antiCU1-70 autoantibody creation. These T cells express RORt and produce IL-17A also. Furthermore, the U1-70Cparticular Compact disc4+ T cells that generate IL-17A are discovered within a subset of sufferers Dovitinib with SLE and so are significantly elevated in sufferers with blended connective tissues disease. These scholarly research offer equipment for learning antigen-specific POLDS Compact disc4+ T cells in lupus, and show an Dovitinib antigen-specific way to obtain IL-17A in autoimmune disease. Systemic lupus erythematosus (SLE) can be an autoimmune disease where sufferers develop high-titer, specific highly, isotype-switched autoantibodies against DNA- and RNA- filled with autoantigens (1). U1-70, U1-A, and U1-C, with U1-RNA as well as the seven Smith proteins jointly, ...
OBJECTIVE: To compare the clinical, laboratory, and demographic variables of women in our clinic with systemic lupus erythematosus (SLE) who have had a pregnancy resulting in a live birth and identify any correlations with either term or preterm delivery. METHODS: Pregnancies in women with SLE from 1999 to 2001 were retrospectively reviewed. We recorded demographic data, disease activity (SLE Disease Activity Index, SLEDAI), obstetric history, prednisone dosage, other medications taken during pregnancy, history of renal disease, and autoantibody status [including antinuclear antibody, anti-DNA, anticardiolipin IgG (aCL), and lupus anticoagulant (LAC)]. Preterm delivery was defined as gestational age at delivery , 37 weeks. We performed a literature survey using PubMed and the key words SLE, pregnancy, and outcome. RESULTS: Of the 72 pregnancies, 28 (38.9%) resulted in preterm deliveries. There were no significant differences in any demographic or disease variables measured comparing term versus ...
Title:The Neutrophil: An Underappreciated But Key Player in SLE Pathogenesis. VOLUME: 9 ISSUE: 4. Author(s):Neelakshi R. Jog, Roberto Caricchio and Philip L. Cohen. Affiliation:Neelakshi R. Jog, Rheumatology Section, Department of Medicine, Temple University School of Medicine, 1182A MERB, 3500 N. Broad Street, Philadelphia, PA 19140, USA.. Keywords:Innate immunity, lupus, neutrophil.. Abstract:Systemic lupus erythematosus (SLE) is a complex multi-organ autoimmune disease, the pathogenesis of which is still not deciphered. The neutrophil, an innate immune cell critical in controlling infections, has traditionally not been regarded as a contributor to systemic autoimmunity due to its lack of specificity and short lifespan. Many recent findings have instead shown that these cells have a role in regulating the adaptive as well as the innate immune response, and that they may play a key role in the abnormal responses seen in SLE. Neutrophils can secrete various cytokines and cellular mediators that ...
Drug-induced lupus erythematosus (DIL or DILE) is an autoimmune disorder (similar to systemic lupus erythematosus [SLE]) caused by chronic use of certain drugs. These drugs cause an autoimmune response (the body attacks its own cells) producing symptoms similar to those of SLE. There are 38 known medications to cause DIL but there are three that report the highest number of cases: hydralazine, procainamide, and isoniazid. While the criteria for diagnosing DIL has not been thoroughly established, symptoms of DIL typically present as muscle pain and joint pain. Generally, the symptoms recede after discontinuing use of the drugs. Signs and symptoms of drug-induced lupus erythematosus include the following: Joint pain (arthralgia) and muscle pain (myalgia) Fatigue Serositis -inflammation of the tissues lining the heart and lungs. Anti-histone antibodies in 95% of cases These signs and symptoms are not side effects of the drugs taken which occur during short term use. DIL occurs over long-term and ...